ClinicalTrials.gg
Active, not recruitingNCT07723924TrulanceUpdated Oct 29, 2026

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

A Phase 2 interventional study of plecanatide and Placebo in Functional Constipation (FC), sponsored by Bausch Health Americas, Inc.. Active, not recruiting at 29 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Updated Oct 29, 2026Now Active, not recruitingNow Recruiting+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Planned enrollment
10th of 12
180 · median 800
Started
2026
the only one that year
Phase 2
5 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 2, and was the 12th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

The goal of this clinical trial is to learn if plecanatide can treat functional constipation in children and adolescents aged 6 to less than 18 years. It will also learn about the safety and pharmacokinetics of plecanatide in this population. The main questions it aims to answer are:

  • Does plecanatide increase the number of spontaneous bowel movements compared to placebo after 8 weeks of treatment?
  • What medical problems do participants experience when taking plecanatide? Researchers will compare low-dose plecanatide and high-dose plecanatide to placebo to see if plecanatide improves bowel movement frequency, stool consistency, and constipation-related symptoms.

Participants will:

  • Complete a screening period with daily electronic diary entries to record bowel movements, symptoms, and rescue medication use
  • Take plecanatide or placebo by mouth once daily for 8 weeks
  • Continue daily electronic diary entries throughout the study
  • Attend clinic visits for physical exams, laboratory tests, and assessments of symptoms and safety
  • Provide blood samples for pharmacokinetic and safety evaluations
  • Complete questionnaires about constipation symptoms and quality of life
Read the detailed description

This Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study is designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of plecanatide administered orally once daily in pediatric participants with functional constipation (FC). Approximately 180 participants will be enrolled at up to 30 investigational sites in the United States and randomized in a 1:1:1 ratio to receive low-dose plecanatide, high-dose plecanatide, or matching placebo. Randomization will be stratified by age group (6 to 11 years and 12 to less than 18 years) and sex.

Background and Rationale Functional constipation is a common condition in children and adolescents and is characterized by infrequent bowel movements, hard stool consistency, and associated symptoms such as straining and abdominal discomfort. Available treatment options in the pediatric population are limited, and there remains a need for additional therapies.

Plecanatide is an orally administered guanylate cyclase-C (GC-C) agonist that acts locally in the gastrointestinal tract to increase intestinal fluid secretion and transit. Clinical studies in adults with chronic idiopathic constipation have demonstrated improvements in bowel movement frequency and stool consistency, as well as an acceptable safety profile. The current study is designed to evaluate plecanatide in a pediatric population using a weight-based dosing approach intended to achieve exposure levels comparable to those associated with efficacy in adults.

Study Design The study consists of three periods: a Screening/Baseline Period, an 8-week Treatment Period, and a Post-treatment Follow-up Period. The total duration of participation is approximately 14 weeks (98 days).

During the Screening/Baseline Period (up to 28 days), participants and/or caregivers complete daily assessments using an electronic diary (eDiary) to record bowel movements, stool characteristics, and constipation-related symptoms. Data from the eDiary are used to establish baseline values and confirm eligibility prior to randomization.

Participants who meet all eligibility criteria are randomized on Day 1 and enter the Treatment Period. Study drug is administered once daily for 8 weeks. Participants are required to continue daily eDiary entries throughout the Treatment Period to capture bowel movement frequency, stool consistency, symptom severity, and use of rescue medication.

Following completion of the Treatment Period, participants enter a 2-week Post-treatment Follow-up Period, during which eDiary assessments continue. A final study visit is conducted at the end of follow-up.

Treatment and Randomization Participants are randomized via an interactive web-based system to receive low-dose plecanatide, high-dose plecanatide, or placebo. Dose assignment is based on treatment group and participant body weight at the time of randomization in order to achieve predefined weight-based dosing ranges.

Study drug is administered orally once daily, preferably in the morning, with or without food. Participants who are unable to swallow tablets may have the study drug administered in a suitable alternative form as described in the protocol.

A rescue medication (bisacodyl) is provided for use if a participant has not had a bowel movement for at least 72 hours. Use of rescue medication is recorded in the eDiary and is subject to protocol-defined limitations.

Efficacy Evaluations Efficacy evaluations are based primarily on data collected through the eDiary and participant-reported outcome (PRO) instruments administered at study visits.

The primary efficacy variable is the change from baseline in spontaneous bowel movement (SBM) frequency at Week 8. Secondary efficacy variables include responder endpoints based on SBM and complete spontaneous bowel movement (CSBM) frequency, stool consistency assessed using the Bristol Stool Form Scale (BSFS) or modified BSFS, and changes from baseline in constipation-related symptoms. Additional assessments include time to first bowel movement, use of rescue medication, and global and symptom-specific PRO measures.

Safety Evaluations Safety is monitored throughout the study by assessment of adverse events (AEs), clinical laboratory parameters, vital signs, physical examinations, and electrocardiograms (ECGs).

Gastrointestinal events, including diarrhea, are of particular interest due to the mechanism of action of plecanatide. Criteria for dose interruption or discontinuation are specified in the protocol for participants experiencing clinically significant adverse events.

Treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events will be summarized descriptively by treatment group.

Pharmacokinetic Assessments Pharmacokinetic evaluations include measurement of plasma concentrations of plecanatide and its metabolite at specified time points following dosing. Given the minimal systemic absorption observed in prior studies, PK analyses are exploratory and are intended to further characterize exposure in the pediatric population.

Statistical Considerations Approximately 30 participants per treatment group within each age cohort are planned. The sample size is considered sufficient for evaluation of the primary objective in this Phase 2b study.

The primary efficacy analysis will be performed on the intent-to-treat population using a mixed-effects model for repeated measures, including treatment group, time, and relevant baseline covariates. Secondary endpoints will be analyzed using appropriate statistical methods based on endpoint type.

Safety analyses will be performed on the safety population and will be summarized descriptively.

Data Collection and Study Conduct Study data are collected using electronic case report forms (eCRFs) and participant eDiaries. Compliance with study procedures, including study drug administration and diary completion, is monitored throughout the study.

The study is conducted in accordance with the principles of Good Clinical Practice (GCP), applicable regulatory requirements, and institutional review board or ethics committee approval. Written informed consent and, where applicable, assent are obtained prior to participation.

03

Conditions studied

  • Functional Constipation (FC)

Browse trials for

Keywords

  • constipation
  • pediatric
  • functional constipation
  • chronic idiopathic constipation
  • children
  • plecanatide
  • trulance
  • FC
  • CIC
  • chronic constipation
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:• Male or female children and adolescents aged 6 to \<18 years at time of consent.

  • Diagnosis of functional constipation (FC) based on Rome IV criteria for children/adolescents.
  • Participant and/or legally authorized representative able to provide /assent.
  • Participant/caregiver willing and able to comply with study procedures, including electronic diary (eDiary).
  • Completion of ≥5 out of 7 daily diary entries during each of the 2 baseline weeks.
  • Stable diet for at least 14 days prior to screening.
  • Females of must use highly effective and have negative pregnancy tests.

Exclusion Criteria:

  • Weight \<15 kg at screening/randomization.
  • History of anorectal malformations, neurological deficits, or anatomical abnormalities affecting bowel function.
  • Use of prohibited medications within 15 days prior to randomization (e.g., anticholinergics, 5-HT agents, opioids, other laxatives).
  • Use of any laxatives other than study-provided Dulcolax®.
  • Pregnant or breastfeeding participants.
  • Active eating disorder within the past 6 months.
  • medical conditions (hepatic, renal, gastrointestinal, endocrine, infectious) that may interfere with study.
  • Known to plecanatide.
  • History of drug or alcohol abuse within 12 months.
  • Participation in another clinical trial within 30 days.
  • Non-compliance with eDiary requirements (\<5/7 entries per week).
  • Use of rescue medication more than 2 days per week during baseline.
  • ≥3 spontaneous bowel movements (SBMs) per week during baseline.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Low Dose Plecanatide

    Participants will receive weight-based low-dose plecanatide administered orally once daily for 8 weeks.

    Drug: plecanatide

  • Experimental
    High Dose Plecanatide

    Participants will receive weight-based high-dose plecanatide orally once daily for 8 weeks.

    Drug: plecanatide

  • Placebo comparator
    Placebo

    Participants will receive matching placebo orally once daily for 8 weeks.

    Drug: Placebo

Interventions

  • Plecanatide is administered orally once daily for 8 weeks. Participants receive weight-based dosing corresponding to assigned treatment arm (low-dose or high-dose) to achieve target exposure ranges. Tablets may be taken with or without food and may be swallowed whole or administered in an alternative form if necessary, as specified in the protocol.

  • DrugPlacebo

    Placebo tablets matching plecanatide in appearance are administered orally once daily for 8 weeks. Placebo is used to maintain blinding and is administered under the same conditions as active study drug.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Spontaneous Bowel Movement (SBM) Frequency at Week 8

    Spontaneous bowel movements (SBMs) are defined as bowel movements that occur without the use of rescue medication within the preceding 24 hours. Weekly SBM frequency will be calculated based on daily electronic diary entries. The endpoint is the change from baseline in the number of SBMs per week at Week 8.

    Time frame: Baseline to week 8

Secondary outcomes

  1. Proportion of Participants Who Are SBM Responders at Week 8

    An SBM responder is defined as a participant who achieves an increase from baseline of ≥1 spontaneous bowel movement (SBM) per week. The proportion of responders will be assessed at Week 8 based on electronic diary data.

    Time frame: week 8

  2. Change From Baseline in Weekly Complete Spontaneous Bowel Movement (CSBM) Frequency at Week 8

    Complete spontaneous bowel movements (CSBMs) are defined as SBMs associated with a sensation of complete evacuation. Weekly CSBM frequency will be calculated based on daily electronic diary entries. The endpoint is the change from baseline in the number of CSBMs per week at Week 8.

    Time frame: Baseline to week 8

  3. Change From Baseline in Stool Consistency as Measured by the Bristol Stool Form Scale (BSFS) at Week 8

    Stool consistency will be assessed using the Bristol Stool Form Scale (BSFS) recorded in the electronic diary. Scores range from 1 (hard stools) to 7 (watery stools). The endpoint is the change from baseline in mean BSFS score at Week 8.

    Time frame: Baseline to week 8

  4. Time to First Spontaneous Bowel Movement (SBM)

    Time to first spontaneous bowel movement (SBM) is defined as the time from first dose of study drug to the first SBM recorded in the electronic diary.

    Time frame: up to 8 weeks

  5. Use of Rescue Medication Over 8 Weeks

    Rescue medication use is defined as the number of days participants use rescue medication (bisacodyl) due to lack of bowel movement. Use will be recorded daily in the electronic diary.

    Time frame: Baseline and Weeks 1 through 8

  6. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) is any adverse event that begins or worsens after the first dose of study drug through the end of the follow-up period.

    Time frame: Up to 10 weeks

07

Study locations

29 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 24 industry-sponsored phase 2 interventional studies under Constipation, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 14 months is below that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 10 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
Aug 18, 2026was Jun 2026
Primary completionEst.
Oct 18, 2027
CompletionEst.
Oct 18, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting→Active, not recruiting
changed Oct 2, 2026 · changed Oct 29, 2026
Sites
28 sites added. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • AppleMedical Research Group, Inc · Miami, United Statesno status→Recruiting
  • The Center for Clinical Trials, Inc. · Mobile, United StatesNot yet recruiting→Recruiting
  • Willis Knighton Clinical Research · Shreveport, United StatesNot yet recruiting→Recruiting
  • PriMED Clinical Research · Dayton, United StatesNot yet recruiting→Recruiting
  • Carolina Family Care · Charleston, United StatesNot yet recruiting→Recruiting
  • Austin Regional Clinic · Austin, United StatesNot yet recruiting→Recruiting
Show 28 added (28 United States)
  • University of Alabama at Birmingham/Children's of Alabama · Birmingham, United States
  • The Center for Clinical Trials, Inc. · Mobile, United States
  • The Center for Clinical Trials, Inc. · Saraland, United States
  • HealthStar Research, LLC · Hot Springs, United States
  • Applied Research Center of Arkansas · Little Rock, United States
  • Advanced Research Center, Inc. · Anaheim, United States
  • Sun Valley Research Center · Imperial, United States
  • Center for Clinical Trials, LLC · Paramount, United States
  • Loma Linda University · San Bernardino, United States
  • Direct Helpers Research Center · Hialeah, United States
  • SouthCoast Research Center, Inc. · Miami, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG · Union City, United States
  • AMR Clinical · El Dorado, United States
  • AMR Clinical · Wichita, United States
  • Willis Knighton Clinical Research · Shreveport, United States
  • University of Maryland Baltimore · Baltimore, United States
  • Boys Town National Research Hospital · Boys Town, United States
  • University Hospitals Cleveland Medical Center · Cleveland, United States
  • PriMED Clinical Research · Dayton, United States
  • Cyn3rgy Research · Gresham, United States
  • Frontier Clinical Research, LLC · Scottdale, United States
  • Frontier Clinical Research, LLC · Smithfield, United States
  • Carolina Family Care · Charleston, United States
  • Austin Regional Clinic · Austin, United States
  • Sun Research Institute · San Antonio, United States
  • ClinPoint Trials, LLC · Waxahachie, United States
  • Pediatric Research of Charlottesville, LLC · Charlottesville, United States
  • Frontier Clinical Research, LLC · Kingwood, United States
across 2 updates, Oct 2, 2026 – Oct 7, 2026
Start date
Jun 1, 2026→Aug 18, 2026
Oct 2, 2026
Contact
Study contact now listed: added a•••@bauschhealth.com · •••2756; added w•••@bauschhealth.com · •••8552. See the current contact
Oct 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • AppleMedical Research Group, Inc · Miami, United StatesContact added C•••@aol.com · •••8434Contact added (no phone or email listed)
Oct 2, 2026
Show all 3 updates
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details
  2. Oct 7, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • The Center for Clinical Trials, Inc. · Mobile, United StatesNot yet recruiting→Recruiting
    • Willis Knighton Clinical Research · Shreveport, United StatesNot yet recruiting→Recruiting
    • PriMED Clinical Research · Dayton, United StatesNot yet recruiting→Recruiting
    • Carolina Family Care · Charleston, United StatesNot yet recruiting→Recruiting
    • Austin Regional Clinic · Austin, United StatesNot yet recruiting→Recruiting
  3. Oct 2, 2026
    Active, not recruiting→Recruiting
    28 sites added. AppleMedical Research Group, Inc is now Recruiting
    Show 28 added (28 United States)
    • University of Alabama at Birmingham/Children's of Alabama · Birmingham, United States
    • The Center for Clinical Trials, Inc. · Mobile, United States
    • The Center for Clinical Trials, Inc. · Saraland, United States
    • HealthStar Research, LLC · Hot Springs, United States
    • Applied Research Center of Arkansas · Little Rock, United States
    • Advanced Research Center, Inc. · Anaheim, United States
    • Sun Valley Research Center · Imperial, United States
    • Center for Clinical Trials, LLC · Paramount, United States
    • Loma Linda University · San Bernardino, United States
    • Direct Helpers Research Center · Hialeah, United States
    • SouthCoast Research Center, Inc. · Miami, United States
    • Rophe Adult and Pediatric Medicine/SKYCRNG · Union City, United States
    • AMR Clinical · El Dorado, United States
    • AMR Clinical · Wichita, United States
    • Willis Knighton Clinical Research · Shreveport, United States
    • University of Maryland Baltimore · Baltimore, United States
    • Boys Town National Research Hospital · Boys Town, United States
    • University Hospitals Cleveland Medical Center · Cleveland, United States
    • PriMED Clinical Research · Dayton, United States
    • Cyn3rgy Research · Gresham, United States
    • Frontier Clinical Research, LLC · Scottdale, United States
    • Frontier Clinical Research, LLC · Smithfield, United States
    • Carolina Family Care · Charleston, United States
    • Austin Regional Clinic · Austin, United States
    • Sun Research Institute · San Antonio, United States
    • ClinPoint Trials, LLC · Waxahachie, United States
    • Pediatric Research of Charlottesville, LLC · Charlottesville, United States
    • Frontier Clinical Research, LLC · Kingwood, United States
    Start date Jun 1, 2026→Aug 18, 2026
    Contact Study contact now listed: added a•••@bauschhealth.com · •••2756; added w•••@bauschhealth.com · •••8552. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • AppleMedical Research Group, Inc · Miami, United StatesContact added C•••@aol.com · •••8434Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07723924
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Aug 18, 2026
Primary completion
Oct 18, 2027 (estimated)
Completion
Oct 18, 2027 (estimated)
Last update
Oct 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion